Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients
Authors
Keywords
-
Journal
PLoS One
Volume 10, Issue 8, Pages e0134395
Publisher
Public Library of Science (PLoS)
Online
2015-08-29
DOI
10.1371/journal.pone.0134395
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
- (2015) Christoph Sarrazin et al. ANTIVIRAL RESEARCH
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2
- (2015) E. Lawitz et al. JOURNAL OF HEPATOLOGY
- LO8 : Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study
- (2015) F. Poordad et al. JOURNAL OF HEPATOLOGY
- LP01 : Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCV coinfection: The ALLY-2 study
- (2015) D.L Wyles et al. JOURNAL OF HEPATOLOGY
- LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1
- (2015) P. Kwo et al. JOURNAL OF HEPATOLOGY
- P0773 : The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV
- (2015) C. Sarrazin et al. JOURNAL OF HEPATOLOGY
- In VitroandIn VivoAntiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A
- (2014) Preethi Krishnan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroandIn VivoAntiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450
- (2014) Tami Pilot-Matias et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor
- (2014) Warren Kati et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
- (2014) Maximilian David Schneider et al. ANTIVIRAL RESEARCH
- Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
- (2014) Evguenia S. Svarovskaia et al. CLINICAL INFECTIOUS DISEASES
- Treatment of HCV infection with the novel NS3/4A protease inhibitors
- (2014) Andrea De Luca et al. CURRENT OPINION IN PHARMACOLOGY
- Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir
- (2014) Eric F. Donaldson et al. HEPATOLOGY
- P1230 LACK OF IMPACT OF BASELINE RESISTANCE-ASSOCIATED VARIANTS (RAVS) ON TREATMENT OUTCOME IN THE AVIATOR STUDY WITH ABT-450/R, ABT-333 AND ABT-267, +/– RIBAVIRIN
- (2014) P. Krishnan et al. JOURNAL OF HEPATOLOGY
- Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A
- (2014) David A. DeGoey et al. JOURNAL OF MEDICINAL CHEMISTRY
- All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
- (2014) Michael Manns et al. LANCET
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
- (2014) Eric Lawitz et al. LANCET
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- (2014) Peter Ferenci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
- (2013) Fiona McPhee et al. HEPATOLOGY
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
- (2013) Anna S. Lok et al. JOURNAL OF HEPATOLOGY
- In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir
- (2013) Xiao Tong et al. JOURNAL OF INFECTIOUS DISEASES
- Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients
- (2013) J. Dietz et al. JOURNAL OF VIROLOGY
- Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
- (2013) Kris V Kowdley et al. LANCET
- The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
- (2013) Ralf Bartenschlager et al. NATURE REVIEWS MICROBIOLOGY
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
- (2013) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir
- (2012) Fiona McPhee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The role of resistance in HCV treatment
- (2012) Johannes Vermehren et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b
- (2012) Fumitaka Suzuki et al. JOURNAL OF CLINICAL VIROLOGY
- Antiviral strategies in hepatitis C virus infection
- (2012) Christoph Sarrazin et al. JOURNAL OF HEPATOLOGY
- A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
- (2012) Eric J. Lawitz et al. JOURNAL OF HEPATOLOGY
- Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
- (2012) Yoshiyuki Suzuki et al. JOURNAL OF HEPATOLOGY
- Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
- (2012) Doug J. Bartels et al. JOURNAL OF VIROLOGY
- Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution
- (2011) Sharlene R. Lim et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks
- (2011) Christoph Sarrazin et al. GASTROENTEROLOGY
- Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
- (2011) Robert A. Fridell et al. HEPATOLOGY
- Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
- (2010) R. A. Fridell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
- (2010) O. Lenz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy
- (2008) Silvana Gaudieri et al. HEPATOLOGY
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
- (2008) Thomas Kuntzen et al. HEPATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now